Search

Displaying results 2471 - 2480 of 10000 in total
  1. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.

  2. Drug

    Brentuximab vedotin

    go.drugbank.com/drugs/DB08870
    ApprovedInvestigational

    Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). … It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011.

  3. Drug

    Dimethyl sulfoxide

    go.drugbank.com/drugs/DB01093
    ApprovedInvestigationalVet approved

    A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Hydracarbazine

    go.drugbank.com/drugs/DB09243
    Experimental

    Hydracarbazine is a pyridazine that has found use as an antihypertensive agent [A19790] It was once marketed in France under the tradename Normatensyl.

  5. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    [A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709] … Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.

  6. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of

  7. Drug

    Obinutuzumab

    go.drugbank.com/drugs/DB08935
    ApprovedInvestigational

    [L54521] It was developed as a Type II anti-CD20 antibody to improve upon first-generation agents like rituximab. … [L54521] Like other drugs in its class, obinutuzumab targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, mediating B-cell lysis.

  8. Drug

    Albutrepenonacog alfa

    go.drugbank.com/drugs/DB13884
    Approved

    [A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016. … It is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305]

  9. Drug

    Zimelidine

    go.drugbank.com/drugs/DB04832
    ApprovedWithdrawn

    Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. … Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving

  10. Drug

    Dotatate gallium Ga-68

    go.drugbank.com/drugs/DB13925
    ApprovedInvestigationalWithdrawn

    [A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016. … Ga-68 dotatate has a high affinity for somatostatin-2 receptor and it is rapidly excreted from the nontarget sites which gives it an ideal candidate for imaging neuroendocrine tumors.